33 results
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
thereunder rather than complying with Nasdaq corporate governance standards. We may choose to take advantage of the following exemptions afforded to foreign … .
Furthermore, Nasdaq Rule 5615(a)(3) provides that a foreign private issuer, such as us, may rely on our home country corporate governance practices
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Current report (foreign)
4:06pm
an agent of the Company
Power to appoint an attorney or authorised signatory of the Company
Borrowing Powers
Corporate Governance
Meetings of Directors … shall establish an audit committee, a compensation committee and a nominating and corporate governance committee. Each of these committees shall
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
that a foreign private issuer, such as us, may rely on our home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule … the independence requirements of Rule 5605(c)(2)(A)(ii). If we rely on our home country corporate governance practices in lieu of certain of the rules of Nasdaq
F-3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
5 Dec 23
Shelf registration (foreign)
4:06pm
and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. We may choose to take advantage of the following … corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d),
provided that we nevertheless comply
6-K
EX-99.4
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
8 Nov 23
Current report (foreign)
4:11pm
Power to appoint an agent of the Company
Power to appoint an attorney or authorised signatory of the Company
Borrowing Powers
Corporate Governance
Meetings … , a compensation committee and a nominating and corporate governance committee. Each of these committees shall be empowered to do all things necessary to exercise
6-K
EX-99.1
11dhui6p s8px81l7nx
8 Nov 23
Current report (foreign)
4:11pm
6-K
kzc4sp7y bmveu8fjv
4 Oct 23
Current report (foreign)
7:24am
424B3
g8x3fwald2 741
31 Mar 23
Prospectus supplement
4:04pm
424B3
y2aq3xqyml4
2 Dec 22
Prospectus supplement
4:17pm
F-1
1tode75yz
18 Nov 22
Registration statement (foreign)
5:39pm
20-F
4qjzmrtdz6ax9ysdw8nu
12 Aug 22
Annual report (foreign)
4:20pm
6-K
ifahfko6r
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.1
l3npetzguydek9nz8i0w
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.3
e8xhlbjan mvy58o1d
26 Jul 22
Current report (foreign)
7:36am
6-K
EX-99.2
sfzw2rvftsne3c
26 Jul 22
Current report (foreign)
7:36am
424B4
bl5x7p5i1 3ntun02
21 Jul 22
Prospectus supplement with pricing info
10:01am
FWP
siwb esk1d
30 Jun 22
Free writing prospectus
9:04pm
FWP
coor0
30 Jun 22
Free writing prospectus
1:29pm
F-1/A
uckkt
24 Jun 22
Registration statement (foreign) (amended)
9:47pm